Magnetic resonance imaging in a patient with peripartum cardiomyopathy

Internal Medicine

Volumn 47, Issue 2, 2008, Pages 97-102

  Kawano, Hiroaki ^a   Tsuneto, Akira ^a   Koide, Yuji ^a   Tasaki, Hirofumi ^a   Sueyoshi, Eijun ^a   Sakamoto, Ichiro ^a   Hayashi, Tomayoshi ^b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANDESARTAN; CARVEDILOL; CREATINE KINASE; GADOLINIUM; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPIRONOLACTONE; TRIACYLGLYCEROL; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOMEGALY; CARDIOMYOPATHY; CASE REPORT; CELL INFILTRATION; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; CONVALESCENCE; DIAGNOSTIC VALUE; ELECTROCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG ARTERY PRESSURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT TRANSPORT; PERINATAL PERIOD; PREDICTION; THIRD TRIMESTER PREGNANCY; THORAX RADIOGRAPHY; CONGESTIVE CARDIOMYOPATHY; HEART BUNDLE BRANCH BLOCK; HEART MUSCLE; HEART VENTRICLE; IMAGE ENHANCEMENT; METHODOLOGY; PATHOLOGY; PUERPERAL DISORDER; PUERPERIUM;

ADULT; BUNDLE-BRANCH BLOCK; CARDIOMYOPATHY, DILATED; FEMALE; GADOLINIUM DTPA; HEART VENTRICLES; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; POSTPARTUM PERIOD; PUERPERAL DISORDERS;

EID: 38749088366     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0316     Document Type: Article

References (25)

1. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 44: 964-968, 1971.
2. Pearson GD, Veille JC, Rahimtoola SH, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283: 1183-1188, 2000.
3. Ibrahim T, Nekolla SG, Hornke M, et al. Quantitative measurement of infarct size by contrast-enhanced magnetic resonance imaging early after acute myocardial infarction: comparison with single-photon emission tomography using Tc99 m-sestamibi. J Am Coll Cardiol 45: 544-552, 2005.
4. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43: 2260-2264, 2004.
5. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108: 54-59, 2003.
6. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to himology and molecular pathology. Circulation 109: 1250-1258, 2004.
7. Abdel-Aty H, Boye P, Zagrozek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45: 1815-1822, 2005.
8. De Cobelli F, Pieroni M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol 47: 1649-1654, 2006.
9. O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 8: 52-56, 1986.
10. Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 74: 474-477, 1994.
11. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J 56: 285-291, 1986.
12. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation 81: 922-928, 1990.
13. Melvin KR, Richardson PJ, Olsen EG, Daly K, Jackson G. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 307: 731-734, 1982.
14. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 18: 619-624, 1987.
15. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gyn 193: 363-365, 2005.
16. Maisch B, Lamparter S, Ristic A, Pankuweit S. Pregnancy and cardiomyopathies. Herz 28: 196-208, 2003 (in German).
17. Farber PA, Glasgow LA. Viral myocarditis during pregnancy: encephalomyocarditis virus infection in mice. Am Heart J 80: 96-102, 1970.
18. Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 23: 289-312, 2002.
19. Jackson E, Bellenger N, Seddon M, Harden S, Peebles C. Ischaemic and non-ischaemic cardiomyopathies-cardiac MRI appearances with delayed enhancement. Clin Cardiol 62: 395-403, 2007.
20. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischemic cardiomyopathies. Eur Hear J 26: 1461-1474, 2005.
21. Lammerding J, Lee RT. Torn apart: membrane rupture in muscular dystrophies and associated cardiomyopathies. J Clin Invest 117: 1749-1752, 2007.
22. Lamparter S, Pankuweit S, Maisch B. Clinical and immunohistologic characteristics in peripartum carduimyopathy. Int J Cardiol 118: 14-20, 2007.
23. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 286: H83-H90, 2003.
24. Nimata M, Kishimoto C, Yuan Z, Shioji K. Beneficial effects of olmesartan, a novel angiotensin II type 1 receptor antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 259: 217-222, 2004.
25. Tachikawa H, Kodama M, Hui L, et al. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol 41(Suppl 1): S105-S110, 2003.